Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis

source extracted confidence: high 2026-04-09
#humans #melatonin #cardiometabolic-risk-factors #dietary-supplements #randomized-controlled-trials-as-topic

Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis

Mohammadi et al., 2025 | Nutrients | Meta Analysis

Citation

Mohammadi Shooka, Ashtary-Larky Damoon, ... Reiter Russel J. Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis. Nutrients. 2025-Dec-31;18(1). doi:10.3390/nu18010134

Abstract

Background/Objectives: There is no definitive consensus regarding the effects of melatonin on cardiometabolic risk factors (CMRFs). This systematic review and dose-response meta-analysis of randomized controlled trials (RCTs) evaluated the impacts of melatonin supplementation on CMRFs, including anthropometric, lipid, glycemic, inflammatory, oxidative, and liver function parameters. Methods: A systematic search across multiple databases retrieved 63 eligible RCTs published up to October 2025. Results: This random-effects meta-analysis indicated that melatonin supplementation significantly reduced hip circumference (weighted mean difference (WMD): -1.18 cm, 95% confidence interval (CI): -2.28, -0.08), systolic blood pressure (WMD: -2.34 mmHg, 95% CI: -4.13, -0.55), fasting blood glucose (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10), low-density lipoprotein cholesterol (WMD: -6.28 mg/dL, 95% CI: -10.53, -2.03), total cholesterol (WMD: -6.97 mg/dL, 95% CI: -12.20, -1.74), C-reactive protein (WMD: -0.59 mg/L, 95% CI: -0.94, -0.23), malondialdehyde (WMD: -1.54 μmol/L, 95% CI: -2.07, -1.01), tumor necrosis factor-alpha (WMD: -1.61 pg/mL, 95% CI: -2.31, -0.90), interleukin-6 (WMD: -6.43 pg/mL, 95% CI: -10.72, -2.15), and alanine aminotransferase (WMD: -2.61 IU/L, 95% CI: -4.87, -0.34). Supplementation with melatonin substantially increased serum total antioxidant capacity (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) and high-density lipoprotein cholesterol (WMD: 2.04 mg/dL, 95% CI: 0.50, 3.57). No significant effects of melatonin were observed on body weight, waist circumference, body fat percentage, body mass index, fasting insulin, homeostasis model assessment of insulin resistance, hemoglobin A1c, triglycerides, diastolic blood pressure, aspartate aminotransferase, or gamma-glutamyl transferase. Conclusions: Melatonin supplementation significantly ameliorated multiple CMRFs.

Key Findings

This random-effects meta-analysis indicated that melatonin supplementation significantly reduced hip circumference (weighted mean difference (WMD): -1.18 cm, 95% confidence interval (CI): -2.28, -0.08), systolic blood pressure (WMD: -2.34 mmHg, 95% CI: -4.13, -0.55), fasting blood glucose (WMD: -11.63 mg/dL, 95% CI: -19.16, -4.10), low-density lipoprotein cholesterol (WMD: -6.28 mg/dL, 95% CI: -10.53, -2.03), total cholesterol (WMD: -6.97 mg/dL, 95% CI: -12.20, -1.74), C-reactive protein (WMD: -

Outcomes Measured

  • blood pressure
  • systolic blood pressure
  • diastolic blood pressure
  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition blood pressure

MeSH Terms

  • Humans
  • Melatonin
  • Cardiometabolic Risk Factors
  • Dietary Supplements
  • Randomized Controlled Trials as Topic
  • Blood Glucose
  • Blood Pressure
  • Dose-Response Relationship, Drug
  • Male
  • Female
  • C-Reactive Protein
  • Middle Aged
  • Cardiovascular Diseases
  • Antioxidants

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Systematic Review, Meta-Analysis
  • Vertical: melatonin

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09